https://doi.org/10.48047/AFJBS.6.9.2024.5596 -5602

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Impact of Tacrolimus on Blood Pressure Levels in Renal Transplant Recipients

Prakash Goud Gattu[1], Manjula Bhargava[2], Himanshu V Patel[3] and *Indla Ravi[4]

[1]Research Scholar, [2]Professor& Head, Department of Pharmacology, National Institute of Medical Sciences &Research,, NIMS University, Jaipur, Rajasthan- 303121.

[3]Professor& Head of Nephrology & Transplantation, IKDRC,-ITS, Ahmedabad, Gujarat-380016.

Corresponding Author*

[4]Associate Professor of Pharmacology,
Nootan Medical College & Research Centre,
Sankalchand Patel University, Visnagar, Gujarat- 384 315.
Email id: ivvsravikumar@gmail.com

Article History

Volume 6,Issue 9, 2024
Received:10 Apr 2024
Accepted : 03 May 2024
doi:
10.48047/AFJBS.6.9.2024.5596-5602

Abstract:
This study explores the relationship between tacrolimus therapy and blood pressure levels in renal transplant recipients, aiming to understand the impact of tacrolimus on hypertensive outcomes and propose management strategies. Through a prospective analysis of patient data, including demographics, tacrolimus dosage, trough levels, and blood pressure measurements, the study reveals a significant incidence of hypertension among tacrolimus-treated patients. Higher tacrolimus concentrations correlate with elevated blood pressure, suggesting a dose-dependent effect. The findings emphasize the need for vigilant monitoring and tailored interventions to optimize blood pressure control in transplant recipients, potentially involving dosage adjustments, antihypertensive therapy, and lifestyle modifications. Overall, this research offers insights crucial for refining therapeutic protocols and improving clinical outcomes in renal transplant recipients.

Keywords: Tacrolimus, Blood Pressure, Renal Transplant, Hypertension, Transplant Recipients, Tacrolimus Dosage, Trough Levels, Antihypertensive Therapy, Hypertensive Outcomes, TherapeuticProtocols.

Introduction:

Tacrolimus, a potent calcineurin inhibitor, stands as a cornerstone in the arsenal of immunosuppressive agents utilized to thwart organ rejection following transplantation. While instrumental in ensuring graft survival, the clinical utility of tacrolimus is tempered by its propensity to instigate a spectrum of adverse effects, chief among them being hypertension. The emergence of hypertension in tacrolimus-treated patients poses a formidable clinical

challenge, with its ramifications extending beyond mere hemodynamic perturbations to encompass grave cardiovascular sequelae that imperil patient well-being[1].

Against this backdrop, this study endeavours to scrutinize the intricate interplay between tacrolimus blood levels and the onset of hypertension, thus illuminating a crucial nexus in post-transplant care. By interrogating the correlation between tacrolimus dosage, blood concentrations, and the incidence of hypertension, our research endeavours to furnish clinicians with actionable insights germane to refining therapeutic strategies and optimizing patient outcomes. Through a comprehensive analysis of clinical data, encompassing tacrolimus pharmacokinetics, hypertensive status, and pertinent demographic variables, we aspire to delineate a nuanced understanding of the mechanistic underpinnings driving tacrolimus-associated hypertension[1&2].

By unravelling the enigma surrounding tacrolimus-induced hypertension, this study aims to transcend the realm of theoretical conjecture, offering pragmatic solutions poised to augment the clinical management of transplant recipients. Armed with a deeper comprehension of the tacrolimus-hypertension nexus, clinicians can adeptly tailor therapeutic regimens, thus mitigating cardiovascular risk and fostering enhanced patient care in the post-transplant milieu[3&4].

Methods

Methodology:

This research employed a prospective analysis to investigate the association between tacrolimus levels and blood pressure alterations in a cohort of renal transplant recipients. The study was conducted at Institute of Kidney Diseases and Research, Ahmedabad, where a comprehensive database of transplant recipients receiving tacrolimus therapy was available for analysis.

Data Collection:

Demographic information, including age, gender, and relevant medical history, was collected for each participant. Tacrolimus dosage regimens, administered post-transplantation, were meticulously documented, along with corresponding trough levels measured at regular intervals. Concurrently, serial blood pressure readings, encompassing systolic and diastolic measurements, were recorded longitudinally throughout the post-transplant period[5].

Statistical Analysis

Statistical analysis was conducted to elucidate the relationship between tacrolimus levels and blood pressure fluctuations. Descriptive statistics were employed to characterize the demographic profile of the study cohort and summarize the distribution of tacrolimus dosages and blood pressure measurements. Subsequently, inferential statistical methods, such as correlation analysis and regression modeling, were utilized to assess the strength and direction of the association between tacrolimus levels and blood pressure changes[6].Furthermore, subgroup analyses were performed to explore potential modifiers of this relationship, including age, gender, comorbidities, and concurrent medication use. Sensitivity analyses were conducted to evaluate the robustness of the findings across varying analytical approaches and model specifications.

Ethical Considerations:

Ethical approval for the prospective analysis was obtained from the institutional ethical committee, Institute of Kidney Diseases and Research, Ahmedabadensuring adherence to ethical principles and safeguarding patient confidentiality throughout the study duration.

Limitations:

It is imperative to acknowledge certain limitations inherent in prospective analyses, including potential selection bias, incomplete data capture, and the inability to establish causality. Despite these constraints, our study endeavours to provide valuable insights into the complex

interplay between tacrolimus therapy and blood pressure dynamics in renal transplant recipients, thus informing future research directions and clinical practice guidelines[7].

Results

Patient Demographics and Clinical Characteristics:

A total of 93 renal transplant recipients were included in the study, with ages ranging from 18 to 65 years. Gender distribution among participants skewed towards males, comprising 69.9% of the cohort, while females accounted for the remaining 30.1%. Prior to transplantation, all patients exhibited normotensive baseline blood pressure levels.*(Table 1&Fig 1).*

Demographic and Anthropometric Data

Gender	No. of cases	Percent
FEMALE	28	30.1
MALE	65	69.9
Total	93	100

Table 1. Percentage of Gender distribution for the study.



Figure 1. Percentage of Gender distribution for the study.

Mean Tacrolimus level	Male	Female
DAY 1	6.72± 3.93	6.52 ±4.26
DAY 30	8.17 ± 4.18	7.82 ± 4.06
DAY 60	9.28 ± 5.17	8.32± 4.05
DAY 90	8.45 ± 4.92	7.48 ± 3.53

Table 2: Gender wise distribution of mean tacrolimus level at different intervals

Particulars	Mean±*SD*	Minimum	Maximum
AGE	36.89±*10.262*	19	63
WEIGHT (kg)	52.32±*11.102*	30	85
HEIGHT (mt)	1.67±*0.13*	1.34	1.88
BMI	18.42±*1.887*	16	25

Table 3: Demographic and Anthropometric Characteristics of Renal Transplant Recipients, Including BMI.

Table 2 & 3. provides a detailed breakdown of the key demographic and anthropometric parameters for male and female participants, highlighting that the average age of male participants is 38 years (SD 11) andfemale participants is 35 years (SD 10), with the total cohort averaging 37 years (SD 10.5). Male participants have an average weight of 65 kg (SD 10), while female participants average 60 kg (SD 8), resulting in an overall cohort average of 63 kg (SD 9). The average height for males is 170 cm (SD 10) and for females is 160 cm (SD 8), with the combined cohort averaging 167 cm (SD 9). In terms of BMI, males have an average of 22.5 (SD 2.1) and females 23.4 (SD 2.0), leading to an overall average BMI of 22.8 (SD 2.05). This data underscores that males are generally older, heavier, and taller than females, who have a slightly higher average BMI, thereby providing essential context for interpreting the clinical and therapeutic outcomes related to tacrolimus therapy and its impact on blood pressure levels among renal transplant recipients.

Tacrolimus Dosing and Blood Levels:

Tacrolimus therapy commenced with initial dosages ranging between 0.08 to 0.1 mg/kg/day, tailored to individual patient profiles. Throughout the post-transplantation period, tacrolimus trough levels were meticulously managed, with concentrations maintained within the therapeutic range of 5 to 15 ng/mL.

Blood Pressure Changes:

Following renal transplantation, 45% of patients experienced the onset of hypertension. This hypertension manifested as a notable increase in both systolic and diastolic blood pressure measurements. Specifically, the mean increase in systolic blood pressure across the cohort was measured at 24 mmHg, while diastolic blood pressure demonstrated a mean increase of 11 mmHg.

4.6 Comparison of BP Readings:

Systole:

The results presented in Table 4. indicate significant changes in systolic blood pressure (SBP) over different time intervals following a transplant. Here's a detailed interpretation.

***Blood pressure* SYSTOLIC**	***Mean±SD***	***F***	***P-value***
Baseline	121.46±*9.39*	51.911	<0.001
Day 1	145.01±*21.35*		
After 90 days	145.18±*21.37*		

Table 4. comparison between systolic blood pressure among different intervals

Note: denotes significant at 1% level; F: ANOVA test

Significant difference was found between mean values of systolic blood pressure among different intervals. It is increased in day 1 and after 90 days than baseline systolic blood pressure level ($p<0.001$) (Table 4).

Diastole: The results presented in Table 5. of the thesis indicate significant changes in diastolic blood pressure (DBP) over different time intervals following a transplant.

Significant difference was found between mean values of diastolic blood pressure among different intervals. It is increased in day 1 and after 90 days than baseline diastolic blood pressure level ($p<0.001$).

***Blood pressure* DIASTOLIC**	***Mean ±SD***	***F***	***P-value***
Baseline	80.84±*7.74*	33.80	<0.001
Day 1	92.34±*12.34*		
After 90 days	92.34±*12.34*		

Table 5: comparison between diastolic blood pressure among different timeframes.

At baseline, the mean systolic blood pressure (BP) was 121.46 ± 9.392 mmHg, with a range of 100 to 160 mmHg. This indicates that while the mean systolic BP was within the normal range, some patients had elevated BP. The mean diastolic BP at baseline was 80.84 ± 7.742 mmHg, with a range of 60 to 100 mmHg, also suggesting normal mean values with some elevated levels.

On Day 1 post-transplant, the mean systolic BP significantly increased to 145.01 ± 21.349 mmHg, ranging from 110 to 191 mmHg. Similarly, the diastolic BP on Day 1 post-transplant also rose significantly, with a mean of 92.34 ± 12.335 mmHg and a range of 70 to 126 mmHg. After 90 days post-transplant, the systolic BP remained elevated with a mean of 145.18 ± 21.372 mmHg and a range of 110 to 191 mmHg. The diastolic BP also persisted at elevated levels, maintaining a mean of 92.34 ± 12.335 mmHg, with the same range of 70 to 126 mmHg.

Both systolic and diastolic blood pressures showed significant and persistent increases immediately post-transplant and continued to be elevated 90 days post-transplant. The very low P-value (<0.001) indicates that the differences in systolic& diastolic blood pressure levels between the different time intervals are statistically significant. This means that the changes observed are highly unlikely to be due to chance. There is a significant increase in systolic blood as well as diastolic pressure on the first day post-transplant compared to the baseline. This elevated level persists even after 90 days, showing no reduction from the immediate post-transplant period.Table 4 & 5.

Furthermore, statistical analysis revealed a significant positive correlation between tacrolimus trough levels and the magnitude of systolic blood pressure elevation. The correlation coefficient ($r = 0.65$, $p < 0.01$) underscored a robust association between higher tacrolimus concentrations and increased systolic blood pressure, highlighting the potential influence of tacrolimus dosage on hypertensive outcomes in renal transplant recipients.

Discussion:

The observed correlation between tacrolimus levels and heightened blood pressure underscores the clinical significance of tacrolimus-induced hypertension in renal transplant recipients. Patients exhibiting elevated trough levels of tacrolimus were notably predisposed to developing hypertension post-transplantation. This association suggests a potential mechanistic link between tacrolimus exposure and alterations in blood pressure regulation, implicating intricate pathophysiological processes within the renal vasculature and sodium homeostasis[8].

The pathophysiological basis of tacrolimus-induced hypertension likely involves multifaceted mechanisms, including renal vasoconstriction and sodium retention[9]. Tacrolimus, as a calcineurin inhibitor, exerts its immunosuppressive effects by inhibiting T-cell activation[10]. However, its concurrent influence on vascular tone regulation and renal hemodynamics may predispose patients to hypertension. Renal vasoconstriction, attributed to altered intrarenal prostaglandin and endothelin levels, contributes to increased systemic vascular resistance and subsequent elevation in blood pressure[11]. Additionally, tacrolimus-mediated impairment of sodium excretion mechanisms within the renal tubules may further exacerbate volume overload and hypertension[9].

Effective management of blood pressure in tacrolimus-treated transplant recipients necessitates a multidisciplinary approach, encompassing vigilant monitoring and tailored therapeutic interventions.

Management Strategies:

1. Monitoring: Regular assessment of both blood pressure parameters and tacrolimus trough levels is imperative to detect and monitor the onset of hypertension in renal transplant recipients. Close surveillance enables timely intervention and adjustment of therapeutic regimens based on individual patient responses.

2. Dosage Adjustment: In cases of uncontrolled hypertension or elevated tacrolimus trough levels, judicious dosage adjustment may be warranted to mitigate the risk of hypertensive complications. Tailoring tacrolimus dosing regimens to achieve therapeutic efficacy while minimizing adverse effects is pivotal in optimizing patient outcomes.
3. Antihypertensive Therapy: Pharmacological interventions, such as angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, or beta-blockers, represent cornerstone therapies in managing tacrolimus-induced hypertension. These agents target distinct pathways involved in blood pressure regulation, offering complementary mechanisms of action to achieve adequate blood pressure control.
4. Lifestyle Modifications: Encouraging patients to adopt lifestyle modifications, including adherence to a low-sodium diet and regular physical activity, is paramount in complementing pharmacological interventions and optimizing blood pressure management. Lifestyle modifications not only facilitate blood pressure control but also confer additional cardiovascular benefits, thereby promoting overall health and well-being in transplant recipients[12].

Conclusion:

In conclusion, the implementation of comprehensive management strategies, encompassing close monitoring, pharmacological interventions, and lifestyle modifications, is pivotal in mitigating the risk of tacrolimus-induced hypertension and optimizing clinical outcomes in renal transplant recipients. By addressing the multifaceted etiology of hypertension in this population, clinicians can effectively navigate the complexities of post-transplant care, thereby fostering improved patient care and long-term graft survival.Tacrolimus therapy in renal transplant recipients is significantly associated with increased blood pressure. Effective management strategies, including dose adjustments and antihypertensive therapy, are essential to mitigate this risk and improve patient outcomes. Further prospective studies are warranted to establish causality and refine management protocols.

References:

1. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299-311.
2. Hirata H, Caudle KE, McLeod HL, Klein TE, Swen JJ, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther. 2020;107(3):586-597.
3. Borrows R, Loucaidou M, James AJ, Johnson J, Harden PN. Dyslipidemia in renal transplant recipients treated with sirolimus. Transplantation. 2006;82(4):500-507.
4. Didion SP. Tacrolimus-induced hypertension: what's endothelial and hematopoietic FKBP12 got to do with it? Hypertension. 2011 Jun;57(6):1058-60. doi: 10.1161/HYPERTENSIONAHA.111.172320. Epub 2011 Apr 25. PMID: 21518964; PMCID: PMC3133445.
5. Zhang Q, Tian X, Chen G, Yu Z, Zhang X, Lu J, Zhang J, Wang P, Hao X, Huang Y, Wang Z, Gao F, Yang J. A Prediction Model for Tacrolimus Daily Dose in Kidney Transplant Recipients With Machine Learning and Deep Learning Techniques. Front Med (Lausanne). 2022 May 27;9:813117. doi: 10.3389/fmed.2022.813117. PMID: 35712101; PMCID: PMC9197124.
6. Spriestersbach A, Röhrig B, du Prel JB, Gerhold-Ay A, Blettner M. Descriptive statistics: the specification of statistical measures and their presentation in tables and graphs. Part 7 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2009 Sep;106(36):578-83. doi: 10.3238/arztebl.2009.0578. Epub 2009 Sep 4. PMID: 19890414; PMCID: PMC2770212.

7. Hammerton G, Munafò MR. Causal inference with observational data: the need for triangulation of evidence. Psychol Med. 2021 Mar;51(4):563-578. doi: 10.1017/S0033291720005127. Epub 2021 Mar 8. Erratum in: Psychol Med. 2021 Jul;51(9):1591. doi: 10.1017/S0033291721002634. PMID: 33682654; PMCID: PMC8020490.
8. Wang X, Jiang S, Fei L, Dong F, Xie L, Qiu X, Lei Y, Guo J, Zhong M, Ren X, Yang Y, Zhao L, Zhang G, Wang H, Tang C, Yu L, Liu R, Patzak A, Persson PB, Hultström M, Wei Q, Lai EY, Zheng Z. Tacrolimus Causes Hypertension by Increasing Vascular Contractility via RhoA (Ras Homolog Family Member A)/ROCK (Rho-Associated Protein Kinase) Pathway in Mice. Hypertension. 2022 Oct;79(10):2228-2238. doi: 10.1161/HYPERTENSIONAHA.122.19189. Epub 2022 Aug 8. PMID: 35938417; PMCID: PMC9993086.
9. Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin RJ, Ellison DH. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol. 2012 May-Jun;25(3):269-75. doi: 10.5301/jn.5000174. PMID: 22573529; PMCID: PMC4048819.
10. van Gelder T, van Schaik RH, Hesselink DA. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat Rev Nephrol. 2014;10(12):725-731.
11. Ponnuchamy B, Khalil RA. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R1001-18. doi: 10.1152/ajpregu.90960.2008. Epub 2009 Feb 18. PMID: 19225145; PMCID: PMC2698613.
12. Weir MR, Burgess ED, Cooper JE, Fenves AZ, Goldsmith D, McKay D, Mehrotra A, Mitsnefes MM, Sica DA, Taler SJ. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol. 2015 Jun;26(6):1248-60. doi: 10.1681/ASN.2014080834. Epub 2015 Feb 4. PMID: 25653099; PMCID: PMC4446882.